Global Immuno-oncology Drugs Market Insights and Forecast to 2026

1 Study Coverage

• 1.1 Immuno-oncology Drugs Product Introduction
• 1.2 Market Segments
• 1.3 Key Immuno-oncology Drugs Manufacturers Covered: Ranking by Revenue
• 1.4 Market by Type
  • 1.4.1 Global Immuno-oncology Drugs Market Size Growth Rate by Type
  • 1.4.2 Immune Checkpoint Inhibitors
  • 1.4.3 Monoclonal Antibodies
  • 1.4.4 Cytokine-Based Immunotherapy
  • 1.4.5 Cancer Vaccines
  • 1.4.6 CAR-T Cell Therapy
• 1.5 Market by Application
  • 1.5.1 Global Immuno-oncology Drugs Market Size Growth Rate by Application
  • 1.5.2 Hospitals
  • 1.5.3 Pharmacies
  • 1.5.4 Online Pharmacies
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Immuno-oncology Drugs Market Size, Estimates and Forecasts
  • 2.1.1 Global Immuno-oncology Drugs Revenue 2015-2026
  • 2.1.2 Global Immuno-oncology Drugs Sales 2015-2026
• 2.2 Global Immuno-oncology Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
  • 2.2.1 Global Immuno-oncology Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
  • 2.2.2 Global Immuno-oncology Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Immuno-oncology Drugs Competitor Landscape by Players

• 3.1 Immuno-oncology Drugs Sales by Manufacturers
  • 3.1.1 Immuno-oncology Drugs Sales by Manufacturers (2015-2020)
  • 3.1.2 Immuno-oncology Drugs Sales Market Share by Manufacturers (2015-2020)
• 3.2 Immuno-oncology Drugs Revenue by Manufacturers
  • 3.2.1 Immuno-oncology Drugs Revenue by Manufacturers (2015-2020)
  • 3.2.2 Immuno-oncology Drugs Revenue Share by Manufacturers (2015-2020)
  • 3.2.3 Global Immuno-oncology Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
  • 3.2.4 Global Top 10 and Top 5 Companies by Immuno-oncology Drugs Revenue in 2019
  • 3.2.5 Global Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Immuno-oncology Drugs Price by Manufacturers
• 3.4 Immuno-oncology Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 Immuno-oncology Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Immuno-oncology Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into Immuno-oncology Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Immuno-oncology Drugs Market Size by Type (2015-2020)
  • 4.1.1 Global Immuno-oncology Drugs Sales by Type (2015-2020)
  • 4.1.2 Global Immuno-oncology Drugs Revenue by Type (2015-2020)
  • 4.1.3 Immuno-oncology Drugs Average Selling Price (ASP) by Type (2015-2026)
• 4.2 Global Immuno-oncology Drugs Market Size Forecast by Type (2021-2026)
  • 4.2.1 Global Immuno-oncology Drugs Sales Forecast by Type (2021-2026)
  • 4.2.2 Global Immuno-oncology Drugs Revenue Forecast by Type (2021-2026)
  • 4.2.3 Immuno-oncology Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
• 4.3 Global Immuno-oncology Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

• 5.1 Global Immuno-oncology Drugs Market Size by Application (2015-2020)
  • 5.1.1 Global Immuno-oncology Drugs Sales by Application (2015-2020)
  • 5.1.2 Global Immuno-oncology Drugs Revenue by Application (2015-2020)
  • 5.1.3 Immuno-oncology Drugs Price by Application (2015-2020)
• 5.2 Immuno-oncology Drugs Market Size Forecast by Application (2021-2026)
  • 5.2.1 Global Immuno-oncology Drugs Sales Forecast by Application (2021-2026)
  • 5.2.2 Global Immuno-oncology Drugs Revenue Forecast by Application (2021-2026)
  • 5.2.3 Global Immuno-oncology Drugs Price Forecast by Application (2021-2026)

6 North America

• 6.1 North America Immuno-oncology Drugs by Country
  • 6.1.1 North America Immuno-oncology Drugs Sales by Country
  • 6.1.2 North America Immuno-oncology Drugs Revenue by Country
  • 6.1.3 U.S.
  • 6.1.4 Canada
• 6.2 North America Immuno-oncology Drugs Market Facts & Figures by Type
• 6.3 North America Immuno-oncology Drugs Market Facts & Figures by Application

7 Europe

• 7.1 Europe Immuno-oncology Drugs by Country
  • 7.1.1 Europe Immuno-oncology Drugs Sales by Country
  • 7.1.2 Europe Immuno-oncology Drugs Revenue by Country
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 U.K.
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Immuno-oncology Drugs Market Facts & Figures by Type
• 7.3 Europe Immuno-oncology Drugs Market Facts & Figures by Application

8 Asia Pacific

• 8.1 Asia Pacific Immuno-oncology Drugs by Region
  • 8.1.1 Asia Pacific Immuno-oncology Drugs Sales by Region
  • 8.1.2 Asia Pacific Immuno-oncology Drugs Revenue by Region
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 South Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Taiwan
  • 8.1.9 Indonesia
  • 8.1.10 Thailand
  • 8.1.11 Malaysia
  • 8.1.12 Philippines
  • 8.1.13 Vietnam
• 8.2 Asia Pacific Immuno-oncology Drugs Market Facts & Figures by Type
• 8.3 Asia Pacific Immuno-oncology Drugs Market Facts & Figures by Application

9 Latin America

• 9.1 Latin America Immuno-oncology Drugs by Country
  • 9.1.1 Latin America Immuno-oncology Drugs Sales by Country
  • 9.1.2 Latin America Immuno-oncology Drugs Revenue by Country
  • 9.1.3 Mexico
  • 9.1.4 Brazil
  • 9.1.5 Argentina
• 9.2 Central & South America Immuno-oncology Drugs Market Facts & Figures by Type
• 9.3 Central & South America Immuno-oncology Drugs Market Facts & Figures by Application

10 Middle East and Africa

• 10.1 Middle East and Africa Immuno-oncology Drugs by Country
  • 10.1.1 Middle East and Africa Immuno-oncology Drugs Sales by Country
  • 10.1.2 Middle East and Africa Immuno-oncology Drugs Revenue by Country
  • 10.1.3 Turkey
  • 10.1.4 Saudi Arabia
  • 10.1.5 U.A.E
• 10.2 Middle East and Africa Immuno-oncology Drugs Market Facts & Figures by Type
• 10.3 Middle East and Africa Immuno-oncology Drugs Market Facts & Figures by Application

11 Company Profiles

• 11.1 Amgen, Inc
  • 11.1.1 Amgen, Inc Corporation Information
  • 11.1.2 Amgen, Inc Description and Business Overview
  • 11.1.3 Amgen, Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 Amgen, Inc Immuno-oncology Drugs Products Offered
  • 11.1.5 Amgen, Inc Related Developments
• 11.2 AstraZeneca, Plc
  • 11.2.1 AstraZeneca, Plc Corporation Information
  • 11.2.2 AstraZeneca, Plc Description and Business Overview
  • 11.2.3 AstraZeneca, Plc Sales, Revenue and Gross Margin (2015-2020)
  • 11.2.4 AstraZeneca, Plc Immuno-oncology Drugs Products Offered
  • 11.2.5 AstraZeneca, Plc Related Developments
• 11.3 Bristol-Myers Squibb
  • 11.3.1 Bristol-Myers Squibb Corporation Information
  • 11.3.2 Bristol-Myers Squibb Description and Business Overview
  • 11.3.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
  • 11.3.4 Bristol-Myers Squibb Immuno-oncology Drugs Products Offered
  • 11.3.5 Bristol-Myers Squibb Related Developments
• 11.4 Celgene Corporation
  • 11.4.1 Celgene Corporation Corporation Information
  • 11.4.2 Celgene Corporation Description and Business Overview
  • 11.4.3 Celgene Corporation Sales, Revenue and Gross Margin (2015-2020)
  • 11.4.4 Celgene Corporation Immuno-oncology Drugs Products Offered
  • 11.4.5 Celgene Corporation Related Developments
• 11.5 Eli Lilly and Company
  • 11.5.1 Eli Lilly and Company Corporation Information
  • 11.5.2 Eli Lilly and Company Description and Business Overview
  • 11.5.3 Eli Lilly and Company Sales, Revenue and Gross Margin (2015-2020)
  • 11.5.4 Eli Lilly and Company Immuno-oncology Drugs Products Offered
  • 11.5.5 Eli Lilly and Company Related Developments
• 11.6 Merck & Co.
  • 11.6.1 Merck & Co. Corporation Information
  • 11.6.2 Merck & Co. Description and Business Overview
  • 11.6.3 Merck & Co. Sales, Revenue and Gross Margin (2015-2020)
  • 11.6.4 Merck & Co. Immuno-oncology Drugs Products Offered
  • 11.6.5 Merck & Co. Related Developments
• 11.7 Hoffmann-La Roche AG
  • 11.7.1 Hoffmann-La Roche AG Corporation Information
  • 11.7.2 Hoffmann-La Roche AG Description and Business Overview
  • 11.7.3 Hoffmann-La Roche AG Sales, Revenue and Gross Margin (2015-2020)
  • 11.7.4 Hoffmann-La Roche AG Immuno-oncology Drugs Products Offered
  • 11.7.5 Hoffmann-La Roche AG Related Developments
• 11.8 Johnson & Johnson
  • 11.8.1 Johnson & Johnson Corporation Information
  • 11.8.2 Johnson & Johnson Description and Business Overview
  • 11.8.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
  • 11.8.4 Johnson & Johnson Immuno-oncology Drugs Products Offered
  • 11.8.5 Johnson & Johnson Related Developments
• 11.9 Novartis International AG
  • 11.9.1 Novartis International AG Corporation Information
  • 11.9.2 Novartis International AG Description and Business Overview
  • 11.9.3 Novartis International AG Sales, Revenue and Gross Margin (2015-2020)
  • 11.9.4 Novartis International AG Immuno-oncology Drugs Products Offered
  • 11.9.5 Novartis International AG Related Developments
• 11.10 AbbVie, Inc.
  • 11.10.1 AbbVie, Inc. Corporation Information
  • 11.10.2 AbbVie, Inc. Description and Business Overview
  • 11.10.3 AbbVie, Inc. Sales, Revenue and Gross Margin (2015-2020)
  • 11.10.4 AbbVie, Inc. Immuno-oncology Drugs Products Offered
  • 11.10.5 AbbVie, Inc. Related Developments
• 11.1 Amgen, Inc
  • 11.1.1 Amgen, Inc Corporation Information
  • 11.1.2 Amgen, Inc Description and Business Overview
  • 11.1.3 Amgen, Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 Amgen, Inc Immuno-oncology Drugs Products Offered
  • 11.1.5 Amgen, Inc Related Developments
• 11.12 Sanofi S.A.
  • 11.12.1 Sanofi S.A. Corporation Information
  • 11.12.2 Sanofi S.A. Description and Business Overview
  • 11.12.3 Sanofi S.A. Sales, Revenue and Gross Margin (2015-2020)
  • 11.12.4 Sanofi S.A. Products Offered
  • 11.12.5 Sanofi S.A. Related Developments
• 11.13 EMD Serono, Inc.
  • 11.13.1 EMD Serono, Inc. Corporation Information
  • 11.13.2 EMD Serono, Inc. Description and Business Overview
  • 11.13.3 EMD Serono, Inc. Sales, Revenue and Gross Margin (2015-2020)
  • 11.13.4 EMD Serono, Inc. Products Offered
  • 11.13.5 EMD Serono, Inc. Related Developments
• 11.14 Gilead Sciences Inc.
  • 11.14.1 Gilead Sciences Inc. Corporation Information
  • 11.14.2 Gilead Sciences Inc. Description and Business Overview
  • 11.14.3 Gilead Sciences Inc. Sales, Revenue and Gross Margin (2015-2020)
  • 11.14.4 Gilead Sciences Inc. Products Offered
  • 11.14.5 Gilead Sciences Inc. Related Developments
• 11.15 Prometheus Therapeutics & Diagnostics
  • 11.15.1 Prometheus Therapeutics & Diagnostics Corporation Information
  • 11.15.2 Prometheus Therapeutics & Diagnostics Description and Business Overview
  • 11.15.3 Prometheus Therapeutics & Diagnostics Sales, Revenue and Gross Margin (2015-2020)
  • 11.15.4 Prometheus Therapeutics & Diagnostics Products Offered
  • 11.15.5 Prometheus Therapeutics & Diagnostics Related Developments
• 11.16 Aduro BioTech
  • 11.16.1 Aduro BioTech Corporation Information
  • 11.16.2 Aduro BioTech Description and Business Overview
  • 11.16.3 Aduro BioTech Sales, Revenue and Gross Margin (2015-2020)
  • 11.16.4 Aduro BioTech Products Offered
  • 11.16.5 Aduro BioTech Related Developments
• 11.17 Galena Biopharma
  • 11.17.1 Galena Biopharma Corporation Information
  • 11.17.2 Galena Biopharma Description and Business Overview
  • 11.17.3 Galena Biopharma Sales, Revenue and Gross Margin (2015-2020)
  • 11.17.4 Galena Biopharma Products Offered
  • 11.17.5 Galena Biopharma Related Developments
• 11.18 Bavarian Nordic
  • 11.18.1 Bavarian Nordic Corporation Information
  • 11.18.2 Bavarian Nordic Description and Business Overview
  • 11.18.3 Bavarian Nordic Sales, Revenue and Gross Margin (2015-2020)
  • 11.18.4 Bavarian Nordic Products Offered
  • 11.18.5 Bavarian Nordic Related Developments
• 11.19 Celldex Therapeutics
  • 11.19.1 Celldex Therapeutics Corporation Information
  • 11.19.2 Celldex Therapeutics Description and Business Overview
  • 11.19.3 Celldex Therapeutics Sales, Revenue and Gross Margin (2015-2020)
  • 11.19.4 Celldex Therapeutics Products Offered
  • 11.19.5 Celldex Therapeutics Related Developments
• 11.20 ImmunoCellular Therapeutics
  • 11.20.1 ImmunoCellular Therapeutics Corporation Information
  • 11.20.2 ImmunoCellular Therapeutics Description and Business Overview
  • 11.20.3 ImmunoCellular Therapeutics Sales, Revenue and Gross Margin (2015-2020)
  • 11.20.4 ImmunoCellular Therapeutics Products Offered
  • 11.20.5 ImmunoCellular Therapeutics Related Developments
• 11.21 Incyte
  • 11.21.1 Incyte Corporation Information
  • 11.21.2 Incyte Description and Business Overview
  • 11.21.3 Incyte Sales, Revenue and Gross Margin (2015-2020)
  • 11.21.4 Incyte Products Offered
  • 11.21.5 Incyte Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

• 12.1 Immuno-oncology Drugs Market Estimates and Projections by Region
  • 12.1.1 Global Immuno-oncology Drugs Sales Forecast by Regions 2021-2026
  • 12.1.2 Global Immuno-oncology Drugs Revenue Forecast by Regions 2021-2026
• 12.2 North America Immuno-oncology Drugs Market Size Forecast (2021-2026)
  • 12.2.1 North America: Immuno-oncology Drugs Sales Forecast (2021-2026)
  • 12.2.2 North America: Immuno-oncology Drugs Revenue Forecast (2021-2026)
  • 12.2.3 North America: Immuno-oncology Drugs Market Size Forecast by Country (2021-2026)
• 12.3 Europe Immuno-oncology Drugs Market Size Forecast (2021-2026)
  • 12.3.1 Europe: Immuno-oncology Drugs Sales Forecast (2021-2026)
  • 12.3.2 Europe: Immuno-oncology Drugs Revenue Forecast (2021-2026)
  • 12.3.3 Europe: Immuno-oncology Drugs Market Size Forecast by Country (2021-2026)
• 12.4 Asia Pacific Immuno-oncology Drugs Market Size Forecast (2021-2026)
  • 12.4.1 Asia Pacific: Immuno-oncology Drugs Sales Forecast (2021-2026)
  • 12.4.2 Asia Pacific: Immuno-oncology Drugs Revenue Forecast (2021-2026)
  • 12.4.3 Asia Pacific: Immuno-oncology Drugs Market Size Forecast by Region (2021-2026)
• 12.5 Latin America Immuno-oncology Drugs Market Size Forecast (2021-2026)
  • 12.5.1 Latin America: Immuno-oncology Drugs Sales Forecast (2021-2026)
  • 12.5.2 Latin America: Immuno-oncology Drugs Revenue Forecast (2021-2026)
  • 12.5.3 Latin America: Immuno-oncology Drugs Market Size Forecast by Country (2021-2026)
• 12.6 Middle East and Africa Immuno-oncology Drugs Market Size Forecast (2021-2026)
  • 12.6.1 Middle East and Africa: Immuno-oncology Drugs Sales Forecast (2021-2026)
  • 12.6.2 Middle East and Africa: Immuno-oncology Drugs Revenue Forecast (2021-2026)
  • 12.6.3 Middle East and Africa: Immuno-oncology Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Porter's Five Forces Analysis
• 13.5 Primary Interviews with Key Immuno-oncology Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Immuno-oncology Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details